Humana has added the ReWalk™ Personal Exoskeleton to its Medicare Advantage plans, a move that brings the device to an estimated 16 million members nationwide and places Humana alongside Aetna and United Healthcare as the three largest insurers offering the exoskeleton.
The coverage expansion follows prior authorizations issued by Humana in December 2025 and is part of the company’s broader strategy to leverage technology‑driven care solutions that improve member outcomes and differentiate its MA portfolio in a highly competitive market.
Financially, Humana reported a Q4 2025 net loss of $796 million, up from $693 million in Q4 2024, while full‑year 2025 net income reached nearly $1.2 billion, a 1.6% decline from 2024. Revenue for Q4 2025 was $32.5 billion, up 11.3% year‑over‑year, and full‑year 2025 revenue totaled $129.7 billion, up 10.1% from the prior year—illustrating strong top‑line growth amid margin pressure.
Management has issued 2026 guidance that reflects a lower earnings outlook, citing a “Star Ratings headwind” that will reduce bonus payments for the upcoming year. The company’s focus on technology and data analytics remains, but the guidance signals a cautious view of future profitability amid competitive and regulatory pressures.
CEO Jim Rechtin said, “We continue to feel good about our consumer‑focused strategy and our individual Medicare Advantage membership growth in 2026, which will allow us to build for the future with even better outcomes and experiences.” This statement underscores confidence in growth despite the headwinds highlighted in the guidance.
Investors have focused on the lower 2026 guidance and the Star Ratings headwind, which have outweighed the positive coverage announcement. The ReWalk expansion is a welcome addition to Humana’s benefit portfolio, but it does not offset the broader financial concerns that dominate market sentiment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.